



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 41408

Title: Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment

Reviewer’s code: 03724099

Reviewer’s country: United States

Science editor: Ruo-Yu Ma

Date sent for review: 2018-08-23

Date reviewed: 2018-08-27

Review time: 4 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	(General priority)	Peer-reviewer’s expertise on the topic of the manuscript:
<input type="checkbox"/> Grade E: Do not publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Minor revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Major revision	<input type="checkbox"/> General
		<input type="checkbox"/> Rejection	<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This is a very well written minireview, which is also timely as no other reviews are available on HDACs in esophageal cancer. Few recommended changes and typographical errors need to be corrected as mentioned below. In the abstract and



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

main section, authors mention 'there are four class of HDACs.....that render them possible anti-cancer drugs, which should be rewritten as HDACs are not anti-cancer drugs instead HDAC inhibitors are being studied as anti-cancer drugs. Page 4: Change an histone to a histone Page 5: Change describe to describe Page 11: change anaugmentation to an augmentation Page 11: change Virinostat to Vorinostat Page 11: US FDA has approved 3 HDAC inhibitors, 3rd one is Belinostat approved in 2014 Page 14: delete 'it' from 'it also'

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No